Vendor, Staten Island, NY
Aclid, Inc.
UEI MC9NKY6NRRQ5, CAGE 9BWZ1
1 award and $167,338 obligated between September 12, 2024 and September 12, 2024, 100% under full and open competition, against 6.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $167,338 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Purchase Order | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| HDTRA124P0047Purchase Order, September 12, 2024, Full and Open Competition After Exclusion of Sources, 6 offers | Defense Threat Reduction AgencyDefense Threat Reduction Agency | Sibr Phase I - Aclid Nucleotide Sequencing Research and Development StudyNAICS 541714, PSC AC33 | $167,338 |
- Places of performance
- New York
- Product and service codes
- AC33 National Defense R&D Services; Defense-Related Activities; Experimental Development
- Transactions
- 1 across 1 awards